DTX 301Alternative Names: DTX 301; scAAV8OTC
Latest Information Update: 29 Mar 2017
At a glance
- Originator Dimension Therapeutics
- Class Gene therapies
- Mechanism of Action Gene transference
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Inborn urea cycle disorders